Striverdi Respimat from Boehringer Ingelheim now available

RIDGEFIELD, Conn. — Boehringer Ingelheim on Wednesday announced that its Striverdi Respimat (olodaterol) inhalation spray in 5-mcg dosage strength is now available by prescription in pharmacies across the United States. The medicine is a once-daily treatment for airflow obstruction in patients dealing with chronic obstructive pulmonary disease, including chronic bronchitis and/or emphysema. It should not be used to treat asthma or acute deteriorations of COPD, according to the company.

 

"For over a half century, Boehringer Ingelheim has been a leader in discovering and developing new therapies for respiratory diseases. We're proud to build upon our respiratory heritage by bringing Striverdi Respimat to market as a new COPD maintenance treatment option," said Kathleen M. Dowd, SVP, marketing, Boehringer Ingelheim Pharmaceuticals. "Approximately 15 million Americans have been told by a healthcare provider that they have COPD, and we believe Striverdi Respimat will be a welcome option for providers and patients alike."

 

The company will offer a savings card that will allow most eligible patients to obtain the medication at no cost for a limited time, depending on their insurance coverage. The savings card can be found at Striverdi.com and can be activated at any pharmacy, the company said.